)
Global Newsroom
Recent News Releases
For investor-related news, see our ASX releases on our parent company's website: CSL.com.
University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
Philadelphia, Pa
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
KING OF PRUSSIA, Pa
CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity
King of Prussia, Pa
This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries
Researchers Decipher a New Way that Immune Cells Detect Infections and Cancers
Melbourne, Australia
Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa.
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
King of Prussia, Pa.
CSL Continues to Advance R&D Capabilities
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing
Sydney, Australia
Harvard Business Review Names Paul Perreault Among Best Performing CEOs in the World
King of Prussia, Pa.
Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
CSL Behring Continues to Deliver on its Promise to Alpha1 Patients at the 29th Annual European Respiratory Society Congress
MADRID, Spain
• Focuses on Patients Through Disease Awareness Support Activities
• Hosts Patient-Focused Symposium on Alpha 1 Management
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Melbourne, Australia
- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
Genoa, Italy
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients.
- Presentations include new analysis from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest clinical trial in CIDP.
Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
Global Biotherapeutics Leader CSL Behring Opens Regional Headquarters at Dubai Science Park
Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
CSL Behring Extends Support of World Federation of Hemophilia Programs
Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
CSL Named One of the Best Employers in the US for Diversity
Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9
CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.
Resources for Media
| Fact Sheet |
| Brand Center |
|
Logos, Design Guidelines and more. (Registration required) |
| Brochure |
| See how we are Driven by Our Promise in our 16-page Corporate Brochure. |
Want to know more about how we are sharing stories of biotech's promise?
Read VitaCSL Behring Media Contacts
Natalie de Vane
Corporate Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4468
Jennifer Purdue
Hematology & Thrombosis, Respiratory and Transplant Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4802
Dana Lynch
Immunology & Neurology Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4545
Faraz Kermani
Corporate Inquiries, Europe
Hattersheim am Main, Hesse, Germany
Phone: +49 69 305 17169
CSL Behring Production Sites
Christina Hickie
Broadmeadows, Victoria, Australia
Phone: +61 429 609 762
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.